ArticlePlant cell reports2024
Enhancing salicylic acid levels by its exogenous pretreatment to mitigate Fusarium oxysporum-induced biotic stress in Vigna mungo: defense pathways insights.
Article in Plant cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evolutionary shifts in plant adaptation mediated by phytohormones.Plant communications · 2026Review
- Integrated transcriptomic and metabolomic analysis revealed the response of resistant variety Zhonghua 6 to the infection of Ralstonia solanacearum in peanut.BMC plant biology · 2026Article
- Global transcriptional and metabolic reprogramming underlies Fusarium wilt resistance in figleaf gourd (Cucurbita ficifolia).BMC genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
key messageFusarium oxysporum disrupts redox homeostasis in Vigna mungo, likely by interfering with salicylic acid signaling, which can be ameliorated by boosting PAL and its related pathways via salicylic acid pretreatment. Fusarium oxysporum, a widespread soil-borne fungus, significantly threatens global crops. This study centers on elucidating the infection strategies employed by F. oxysporum against a new and underexplored host Vigna mungo, a leguminous crop of high agronomic value, and the defense mechanisms that can be activated against the infection, aiming to uncover how these responses can be leveraged to develop potential countermeasures. Building on prior work demonstrating the in vitro antifungal efficacy of phytohormones, including salicylic acid (SA), this study further investigates SA pretreatment at 100 µM, which previously reduced reactive oxygen species (ROS) and improved germination under Fusarium stress. Through a comprehensive analysis of V. mungo plants pretreated with SA and subjected to F. oxysporum infection, we observed that fungal exposure reduced growth, chlorophyll content, and levels of proteins, phenolics and flavonoids, while increasing stress markers and antioxidant activity. SA pretreatment mitigated these effects by boosting antioxidant molecules and activating the phenylalanine ammonia-lyase (PAL) pathway, thereby enhancing endogenous SA and ROS scavenging. Furthermore, qRT-PCR analysis confirmed SA-mediated upregulation of antioxidant (catalase and peroxidase), fungal stress response genes ((pathogenesis-related gene 4 (PR4) and defensin (DEF)) and SA synthesis and regulator genes (PAL and WRKY70) involved in plant systemic resistance, while LC-MS data revealed an altered metabolic profile with increased phytoalexins and antioxidants synthesis. Overall, SA pretreatment confers resistance against F. oxysporum in V. mungo by modulating endogenous SA and metabolic profile to activate key defense pathways and redox homeostasis, highlighting its potential in plant defense strategies and reinforcing our proposed model of SA action.
Indexed as
Identifiers
39652267What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.